Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
1.
Acta Otorhinolaryngol Ital ; 41(2): 108-119, 2021 Apr.
Article in English | MEDLINE | ID: mdl-34028455

ABSTRACT

Oral cancer is a heterogeneous disease that develops through a complex, multi-step process. Precision medicine should help to better understand its molecular basis, integrate traditional classifications and have a positive impact on cancer management. To apply this information in clinical practice, we need to define its histology and identify biomarkers expressed by the tumour that provide useful information for planning tailored treatment. The most reliable information currently derives from evaluation of biomarkers on post-operative samples. To plan personalised treatment, oncologists need to assess these markers on biopsy samples. We reviewed the recent literature and identified 6 of 184 publications that compared markers measured on biopsy and post-operative samples or assessed their predictivity for the development of lymph node metastases. Data from these studies suggest that markers measured on biopsy samples can provide useful indications for tailoring treatments. However, due to their heterogeneity and low level of evidence, these results need to be confirmed by clinical studies on a large population to standardise and validate biomarkers in biopsies and to assess their reliability in other diagnostic mini-invasive procedures such as radiomics and liquid biopsy.^ieng


Il cancro orale è una malattia eterogenea che origina ed evolve con un processo complesso e multifasico. La medicina di precisione permette di pianificare un trattamento personalizzato sulla base delle caratteristiche biologiche e molecolari delle singole neoplasie. Le informazioni oggi più affidabili sono fornite dalla valutazione post-operatoria dei biomarcatori, ma per pianificare un trattamento personalizzato è necessario valutare questi marcatori sulla biopsia. Per questo abbiamo rivisto la letteratura dell'ultimo quinquennio ed abbiamo identificato 6/184 articoli che valutano i marcatori sulla biopsia confrontandone i valori con quelli misurati sul pezzo operatorio di ciascun paziente o valutandone la predittività per lo sviluppo di metastasi linfonodali. I dati che emergono da questi studi suggeriscono che la valutazione dei marcatori sul campione bioptico potrebbe fornire indicazioni utili per programmare trattamenti personalizzati. Tuttavia, a causa della eterogeneità e del basso livello di evidenza dei lavori considerati, questi risultati devono essere confermati da studi clinici su un'ampia popolazione per standardizzare e validare i biomarcatori e la loro affidabilità in altre procedure mini-invasive, ad esempio radiomica e biopsia liquida.


Subject(s)
Mouth Neoplasms , Precision Medicine , Biopsy , Humans
2.
Cancers (Basel) ; 12(12)2020 Nov 29.
Article in English | MEDLINE | ID: mdl-33260360

ABSTRACT

Literature on the role of human papillomavirus (HPV) in head and neck cancer (HNC) in Italy is limited, especially for non-oropharyngeal tumours. Within the context of the HPV-AHEAD study, we aimed to assess the prognostic value of different tests or test algorithms judging HPV carcinogenicity in HNC and factors related to HPV positivity at the European Institute of Oncology. We conducted a retrospective cohort study (2000-2010) on a total of 696 primary HNC patients. Formalin-fixed, paraffin-embedded cancer tissues were studied. All HPV-DNA-positive and a random sample of HPV-DNA-negative cases were subjected to HPV-E6*I mRNA detection and p16INK4a staining. Multivariate models were used to assess for factors associated with HPV positivity and proportional hazards for survival and recurrence. The percentage of HPV-driven cases (considering HPV-E6*I mRNA positivity) was 1.8, 2.2, and 40.4% for oral cavity (OC), laryngeal (LC), and oropharyngeal (OPC) cases, respectively. The estimates were similar for HPV-DNA/p16INK4a double positivity. Being a non-smoker or former smoker or diagnosed at more recent calendar periods were associated with HPV-E6*I mRNA positivity only in OPC. Being younger was associated with HPV-E6*I mRNA positivity in LC. HPV-driven OPC, but not HPV-driven OC and LC, showed better 5 year overall and disease-free survival. Our data show that HPV prevalence in OPC was much higher than in OC and LC and observed to increase in most recent years. Moreover, HPV positivity conferred better prognosis only in OPC. Novel insights on the role of HPV in HNC in Italy are provided, with possible implications in the clinical management of these patients.

3.
Head Neck ; 41(3): 821-827, 2019 03.
Article in English | MEDLINE | ID: mdl-30600861

ABSTRACT

BACKGROUND: Surgery of tongue tumors includes different procedures ranging from mucosal resection to complex combined resection. Numerous terms have been used to describe such procedures, but there is no consensus between the terminology and the extent of resection. METHODS AND RESULTS: We searched the medical literature and found a lack of published information. We undertook to describe a new classification of surgical procedures for tongue tumor resection. We based it upon the surgical anatomy of the tongue and the spread of the cancer. We posited that there were five major types of glossectomy embracing all the methods of tongue cancer resection. This classification was reviewed and endorsed by an international team of experts. CONCLUSION: We propose a more precise classification than that currently in practice, thereby bringing clarity and consistency to the terminology, facilitating shared communication between surgeons, comparison between published research, and ultimately improving surgical practice and patient care.


Subject(s)
Glossectomy/classification , Glossectomy/methods , Tongue Neoplasms/surgery , Humans , Tongue Neoplasms/pathology
4.
PLoS Pathog ; 13(3): e1006262, 2017 03.
Article in English | MEDLINE | ID: mdl-28253371

ABSTRACT

UBC9, the sole E2-conjugating enzyme required for SUMOylation, is a key regulator of essential cellular functions and, as such, is frequently altered in cancers. Along these lines, we recently reported that its expression gradually increases during early stages of human papillomavirus (HPV)-mediated cervical lesions transformation. However, a better understanding of how UBC9 is exploited by transforming viral oncoproteins is still needed. In the present study, we show that in human samples HPV drives UBC9 up-regulation also in very early steps of head and neck tumorigenesis, pointing to the important role for UBC9 in the HPV-mediated carcinogenic program. Moreover, using HPV-infected pre-cancerous tissues and primary human keratinocytes as the natural host of the virus, we investigate the pathological meaning and the cellular mechanisms responsible for UBC9 de-regulation in an oncoviral context. Our results show that UBC9 overexpression is promoted by transforming viral proteins to increase host cells' resistance to apoptosis. In addition, ultrastuctural, pharmacological and genetic approaches crucially unveil that UBC9 is physiologically targeted by autophagy in human cells. However, the presence of HPV E6/E7 oncoproteins negatively impacts the autophagic process through selective inhibition of autophagosome-lysosome fusion, finally leading to p53 dependent UBC9 accumulation during viral-induced cellular transformation. Therefore, our study elucidates how UBC9 is manipulated by HPV oncoproteins, details the physiological mechanism by which UBC9 is degraded in cells, and identifies how HPV E6/E7 impact on autophagy. These findings point to UBC9 and autophagy as novel hallmarks of HPV oncogenesis, and open innovative avenues towards the treatment of HPV-related malignancies.


Subject(s)
Autophagy/physiology , Cell Transformation, Viral/physiology , Papillomavirus Infections/metabolism , Ubiquitin-Conjugating Enzymes/metabolism , Apoptosis , Cell Transformation, Neoplastic , Female , Flow Cytometry , Humans , Immunoblotting , Immunohistochemistry , Microscopy, Confocal , Oncogene Proteins, Viral , Papillomaviridae/metabolism , Papillomavirus Infections/pathology , Polymerase Chain Reaction , Transduction, Genetic , Transfection
5.
Head Neck ; 39(1): 71-81, 2017 01.
Article in English | MEDLINE | ID: mdl-27453475

ABSTRACT

BACKGROUND: The purpose of this study was to identify the factors influencing oncologic outcomes for patients with early-intermediate glottic cancer treated by transoral laser microsurgery (TLM). METHODS: This was a retrospective mono-institutional study. A total of 590 patients with cTis-cT3 glottic cancer underwent TLM with curative intent. RESULTS: TLM alone was performed in 538 patients (91.2%) and TLM followed by adjuvant radiotherapy (RT) was done in 52 (8.8%). Five-year recurrence-free survival (RFS) and 10-year overall survival (OS) were 85.3% and 74.7%, respectively. The larynx-preservation ratio was 95.9%. In particular, from our data, we found that occult metastases were rare (1.2%); preventive tracheotomy was not necessary; the local recurrence rate of Tis was similar to that in the T2 and T3 group; and no major or lethal complications were observed. CONCLUSION: Age (>60 vs ≤60), type of cordectomy (≥IV vs ≤III), status of margins, fixed arytenoid, and pathologic T classification, were the variables associated with RFS, OS, and organ-preservation rate. © 2016 Wiley Periodicals, Head Neck 39: 71-81, 2017.


Subject(s)
Carcinoma/surgery , Glottis , Laryngeal Neoplasms/surgery , Laser Therapy , Microsurgery , Adult , Aged , Aged, 80 and over , Carcinoma/mortality , Carcinoma/pathology , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Laryngeal Neoplasms/mortality , Laryngeal Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Retrospective Studies , Survival Rate , Treatment Outcome
6.
Head Neck ; 37(4): 548-56, 2015 Apr.
Article in English | MEDLINE | ID: mdl-24677505

ABSTRACT

BACKGROUND: Preoperative data in patients with oral cavity/oropharyngeal cancer may predict postoperative complications that may modify therapeutic choices and improve patient care. METHOD: We reviewed 320 consecutive patients with oral cavity/oropharyngeal cancer, operated on 2003 through 2006 at the European Institute of Oncology. By multivariate analysis of preoperative patient and tumor characteristics, we developed an algorithm to predict postoperative complications. We tested the algorithm on a new series of 307 patients operated on 2007 through 2010. RESULTS: The final algorithm used to produce a nomogram was comprised of: alcohol consumption (p = .01), site of primary (p = .03), interaction of clinical T classification to sex (p = .007), and type of neck dissection (p < .0001). The algorithm had good ability to predict complications (concordance index [c-index] 0.74) in the new series. CONCLUSION: The nomogram accurately predicts presurgical risk of postoperative local/systemic complications in patients with oral cavity/oropharyngeal cancer and can be used to adapt therapy to patient characteristics, optimize ward admissions, and improve care.


Subject(s)
Algorithms , Mouth Neoplasms/surgery , Nomograms , Oropharyngeal Neoplasms/surgery , Postoperative Complications/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/epidemiology , Comorbidity , Female , Humans , Male , Middle Aged , Mouth Neoplasms/epidemiology , Multivariate Analysis , Oropharyngeal Neoplasms/epidemiology , Respiratory Tract Diseases/epidemiology , Young Adult
7.
Future Oncol ; 10(10): 1735-9, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25303054

ABSTRACT

Malignant tumors of the lacrimal gland are rare, and single bone metastases from lacrimal gland carcinoma are an exceptional event. We present the case of a 71-year-old man with a history of lumbar pain and left exophthalmos. Surgical resection of the lacrimal lesion and a bone biopsy gave a final histopathological diagnosis of primary ductal adenocarcinoma of the lacrimal gland with bone metastasis. The pathological tissue from both procedures was positive for androgen receptor expression. The patient underwent embolization and radiotherapy in association with total androgen blockade. After 20 months, the patient is still asymptomatic and has maintained the partial response at L1 with no progression to other sites. Our patient would appear to have a better prognosis and the disease a more indolent clinical course than the other cases of ductal adenocarcinoma of the lacrimal gland reported in the literature.


Subject(s)
Adenocarcinoma/pathology , Bone Neoplasms/diagnosis , Bone Neoplasms/secondary , Eye Neoplasms/pathology , Lacrimal Apparatus/pathology , Aged , Biopsy , Bone Neoplasms/radiotherapy , Humans , Lumbar Vertebrae/pathology , Magnetic Resonance Imaging , Male , Positron-Emission Tomography , Tomography, X-Ray Computed , Treatment Outcome , Tumor Burden
8.
Diagn Cytopathol ; 42(11): 970-3, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24550235

ABSTRACT

Medullary thyroid carcinoma (MTC) can assume various cytomorphological and architectural forms, mimicking other thyroid and extra-thyroid tumors and rendering the cytological and histological diagnosis challenging. Consequently, measurement of calcitonin (CT) levels is generally considered to be more accurate than cytology in diagnosing MTC. Here, we report on a patient with a multinodular goiter and significantly elevated basal CT levels; based on cytology examination and CT immunocytostains, neither MTC nor C-cell hyperplasia was detected upon final histopathological examination. CT testing has a high false-positive rate and low positive predictive value for detecting clinically relevant MTC. Judicious integration of cytological examination with immunocytochemical stains (when needed) may be useful for selecting the most appropriate therapy and avoiding overtreatment (i.e., central neck lymph node dissection in the present case). This case demonstrates that cytological examination with ancillary techniques is still valuable in patients with thyroid nodules and suspicious MTC.


Subject(s)
Adenocarcinoma, Follicular/diagnosis , Calcitonin/blood , Thyroid Nodule/diagnosis , Adenocarcinoma, Follicular/blood , Adult , Biopsy, Fine-Needle , Female , Humans , Image-Guided Biopsy , Thyroid Gland/pathology , Thyroid Nodule/blood
9.
Int J Med Robot ; 10(1): 107-12, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24288345

ABSTRACT

BACKGROUND: Transoral laser microsurgery (TLM) is a mature approach to supraglottic cancer, while transoral robotic surgery (TORS) is emerging. The present study compared these approaches. METHODS: The first 10 patients (2002-2005) given TLM were compared with the first 10 (2007-2011) given TORS for cT1-3 cN0-cN2c supraglottic cancer. RESULTS: A feeding tube was used in four TLM and seven TORS patients. Margins were more often positive, but operating times shorter, in TORS. All 10 TORS patients are without evidence of disease, but only six TLM patients remain disease-free after much longer follow-up. TORS was considerably less uncomfortable and fatiguing for the surgeon. CONCLUSIONS: TORS seems as safe and effective as TLM. Shorter TORS operating times are probably attributable to prior experience with TLM. For laryngeal exposure, length of tube placement and margin evaluability, TLM was superior; however, this may change as TORS develops and transoral robotic instruments are optimized.


Subject(s)
Laryngeal Neoplasms/surgery , Laryngectomy/methods , Microsurgery/methods , Supraglottitis/surgery , Aged , Carcinoma, Squamous Cell/surgery , Female , Humans , Laser Therapy/methods , Lasers , Male , Middle Aged , Minimally Invasive Surgical Procedures/methods , Pilot Projects , Retrospective Studies , Robotics , Surgery, Computer-Assisted , Treatment Outcome
10.
Tumori ; 99(6): 667-75, 2013.
Article in English | MEDLINE | ID: mdl-24503789

ABSTRACT

AIMS AND BACKGROUND: To achieve the goal of organ preservation, both a chemoradiotherapy and a conservative surgical approach can be proposed. The aim of the study was to review all patients treated in our Institute with conservative surgery and postoperative radiotherapy for locally advanced supraglottic tumor. METHODS AND STUDY DESIGN: A retrospective analysis of 32 patients treated between 2000 and 2010 was performed. Overall survival, disease-free survival and late laryngeal toxicity were evaluated. The impact of surgical procedures, radiotherapy characteristics and addition of chemotherapy on late laryngeal toxicity was studied. RESULTS: The median follow-up was 38 months. Overall survival and disease-free survival at 5 years were 73% and 66%, respectively. Three (9%) patients experienced local recurrence (after 22, 25 and 40 months, respectively) and were treated with total laryngectomy. The larynx preservation rate was 93%. Severe treatment-related late laryngeal toxicity (grade 3 and 4 laryngeal edema, laryngeal stenosis, presence of tracheotomy at last follow-up because of treatment-related toxicity, and the need for enteral nutrition) was experienced by 34% of patients. The functional larynx preservation rate was 81%. The statistically significant risk factors for severe late toxicity were: female gender, extension of the surgical procedure, removal of one arytenoid and association with concomitant chemotherapy. CONCLUSIONS: We confirmed literature data on the feasibility and efficacy of a surgical organ preservation strategy. However, the high incidence of severe late toxicity requires further studies to improve patient selection and to reduce side effects.


Subject(s)
Laryngeal Neoplasms/radiotherapy , Laryngeal Neoplasms/surgery , Laryngectomy/adverse effects , Laryngectomy/methods , Larynx/physiopathology , Organ Sparing Treatments , Aged , Aged, 80 and over , Disease-Free Survival , Dose Fractionation, Radiation , Female , Follow-Up Studies , Humans , Italy , Kaplan-Meier Estimate , Laryngeal Neoplasms/pathology , Laryngeal Neoplasms/physiopathology , Larynx/surgery , Lymphatic Metastasis , Male , Middle Aged , Neck Dissection , Neoplasm Invasiveness , Neoplasm Recurrence, Local/diagnosis , Neoplasm Staging , Radiotherapy, Adjuvant/adverse effects , Recovery of Function , Retrospective Studies , Tracheostomy , Treatment Outcome
11.
Br J Oral Maxillofac Surg ; 51(3): 217-23, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22877706

ABSTRACT

Our aim was to analyse the overall and disease-free survival (DFS), time to recovery of oral feeding, and morbidity, in a consecutive series of patients who had total glossectomy with preservation of the larynx for advanced cancer of the tongue at the European institute of Oncology (Milan). From June 2002 to April 2011, 37 patients who were treated for advanced cancer of the tongue had total glossectomy, bilateral neck dissection, and preservation of the larynx. Various flaps were used for reconstruction. Overall and disease-free survival were assessed from the day of operation to the latest outpatient examination. Postoperative morbidity and rehabilitation of feeding were also assessed. Six patients had major complications, four of whom had a second operation for necrosis of the flap. Actuarial five-year overall survival (OS) and disease-free survival were 54% and 47%. Twenty-four patients (65%) were operated on as their first treatment, and had 79% five-year overall survival and 61% 5-year disease-free survival. Twenty-six patients were eventually able to feed orally postoperatively. Although this retrospective study include a limited number of patients, the results support the validity of total glossectomy as a safe procedure for advanced cancer of the tongue. Pretreated patient were previously treated with surgery, radiotherapy or chemoradiotherapy with curative purposes. Nevertheless, the long period required for recovery of oral feeding indicates that total glossectomy should be reserved for highly motivated patients.


Subject(s)
Glossectomy/methods , Tongue Neoplasms/surgery , Adult , Aged , Chemotherapy, Adjuvant , Deglutition/physiology , Disease-Free Survival , Eating/physiology , Follow-Up Studies , Glossectomy/rehabilitation , Graft Survival , Humans , Larynx/physiology , Middle Aged , Muscle, Skeletal/transplantation , Neck Dissection/methods , Organ Sparing Treatments , Postoperative Complications , Radiotherapy, Adjuvant , Plastic Surgery Procedures/methods , Recovery of Function/physiology , Reoperation , Retrospective Studies , Skin Transplantation/methods , Speech Intelligibility/physiology , Surgical Flaps , Survival Rate , Young Adult
12.
BMC Cancer ; 12: 208, 2012 May 30.
Article in English | MEDLINE | ID: mdl-22646734

ABSTRACT

BACKGROUND: Loco-regionally advanced nasopharyngeal carcinomas can be cured by the combination of chemotherapy and radiotherapy. In Eastern countries, plasma levels of viral Epstein-Barr deoxyribonucleic acid (DNA) are accurate in predicting recurrence, but few data are available in Western populations. The aim of this prospective study was to evaluate the relationship between viral Epstein-Barr DNA copy numbers in plasma and the response rate, progression-free survival and overall survival in a cohort of Western patients with stage IIb-IVb nasopharyngeal cancer. METHODS: We evaluated plasma samples from 36 consecutive patients treated with induction chemotherapy followed by chemoradiation. EBV copy numbers were determined after DNA extraction using real-time quantitative polymerase chain reaction. Survival curves were estimated using the Kaplan-Meier method. RESULTS: Circulating Epstein-Barr virus DNA levels were measured before treatment, at the end of concomitant chemo- and radiotherapy, and during the follow-up period. Pre-treatment levels significantly correlated with the initial stage and probability of relapse. Their increase was 100% specific and 71.3% sensitive in detecting loco-regional or metastatic recurrence (an overall accuracy of 94.4%). Three-year progression-free and overall survival were respectively 78.2% and 97.1%. CONCLUSIONS: The results of this study confirm that patients from a Western country affected by loco-regionally advanced nasopharyngeal carcinoma have high plasma Epstein-Barr virus DNA levels at diagnosis. The monitoring of plasma levels is sensitive and highly specific in detecting disease recurrence and metastases.


Subject(s)
Epstein-Barr Virus Infections/virology , Herpesvirus 4, Human/isolation & purification , Nasopharyngeal Neoplasms/diagnosis , Viral Load , White People , Adult , Carcinoma , DNA, Viral/blood , Female , Humans , Male , Middle Aged , Nasopharyngeal Carcinoma , Nasopharyngeal Neoplasms/mortality , Nasopharyngeal Neoplasms/virology , Neoplasm Staging , Prognosis , Recurrence
13.
Cancer Treat Rev ; 38(8): 1033-49, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22542950

ABSTRACT

PURPOSE: Dysphagia is a debilitating complication in head and neck cancer patients (HNCPs) that may cause a high mortality rate for aspiration pneumonia. The aims of this paper were to summarize the normal swallowing mechanism focusing on its anatomo-physiology, to review the relevant literature in order to identify the main causes of dysphagia in HNCPs and to develop recommendations to be adopted for radiation oncology patients. The chemotherapy and surgery considerations on this topic were reported in recommendations only when they were supposed to increase the adverse effects of radiotherapy on dysphagia. MATERIALS AND METHODS: The review of literature was focused on studies reporting dysphagia as a pre-treatment evaluation and as cancer and cancer therapy related side-effects, respectively. Relevant literature through the primary literature search and by articles identified in references was considered. The members of the group discussed the results and elaborated recommendations according to the Oxford CRBM levels of evidence and recommendations. The recommendations were revised by external Radiation Oncology, Ear Nose and Throat (ENT), Medical Oncology and Speech Language Pathology (SLP) experts. RESULTS: Recommendations on pre-treatment assessment and on patients submitted to radiotherapy were given. The effects of concurrent therapies (i.e. surgery or chemotherapy) were taken into account. CONCLUSIONS: In HNCPs treatment, disease control has to be considered in tandem with functional impact on swallowing function. SLPs should be included in a multidisciplinary approach to head and neck cancer.


Subject(s)
Deglutition Disorders/physiopathology , Deglutition Disorders/radiotherapy , Head and Neck Neoplasms/physiopathology , Head and Neck Neoplasms/radiotherapy , Deglutition Disorders/etiology , Head and Neck Neoplasms/complications , Humans , Radiation Oncology/methods
14.
Int J Cancer ; 130(3): 665-70, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-21400506

ABSTRACT

Only limited data is available on the relationship between family history of laryngeal and other neoplasms and laryngeal cancer risk. We investigated the issue using data from a multicentre case-control study conducted in Italy and Switzerland between 1992 and 2009 including 852 cases with histologically confirmed laryngeal cancer and 1970 controls admitted to hospital for acute, non neoplastic conditions. Unconditional logistic regression models adjusted for age, sex, study center, education, tobacco smoking, alcohol drinking and number of siblings were used to estimate the odds ratios (ORs) of laryngeal cancer. The multivariate OR was 2.8 (95% confidence interval [CI], 1.5-5.3) in subjects reporting a first-degree relative with laryngeal cancer, as compared to subjects with no family history. The OR was higher when the relative was diagnosed before 60 years of age (OR = 3.5, 95% CI 1.4-8.8). As compared to subjects without family history, non-smokers, and moderate drinkers, the OR was 37.1 (95% CI 9.9-139.4) for current smokers, heavy drinkers, with family history of laryngeal cancer. Family history of colorectal (OR = 1.5, 95% CI 1.0-2.3) and kidney (OR = 3.8, 95% CI 1.2-12.1) cancer were also associated to an increased risk of laryngeal cancer, while no significant increase in risk was found for family history of cancer at all sites, excluding the larynx (OR = 1.1).


Subject(s)
Laryngeal Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Case-Control Studies , Family Health , Female , Humans , Italy/epidemiology , Male , Middle Aged , Risk Factors , Switzerland/epidemiology , Young Adult
15.
Crit Rev Oncol Hematol ; 84 Suppl 1: e90-6, 2012 Dec.
Article in English | MEDLINE | ID: mdl-21145755

ABSTRACT

HNC is the 11th most frequent carcinoma with a world-wide yearly incidence exceeding over half a million cases [1], a 10:1 male gender predilection and country specific variability [2]. The principal risk factors are tobacco and alcohol use and, in a growing population without these exposures, HPV infection. While much progress has been made in understanding the molecular basis of cancer, the 5-year mortality of head and neck cancer has remained approximately 50%. To this date we have not been able to translate as much of our basic science knowledge into significant disease altering therapeutic strategies in terms of local, loco-regional, functional and overall survival. Challenges remain in all aspects of head and neck cancer management: prevention, diagnosis, surgical and non-surgical treatment.


Subject(s)
Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/therapy , Animals , Antineoplastic Agents/therapeutic use , Head/pathology , Head/surgery , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/surgery , Humans , Neck/pathology , Neck/surgery , Radiotherapy/methods
16.
Int J Cancer ; 130(11): 2484-94, 2012 Jun 01.
Article in English | MEDLINE | ID: mdl-21796618

ABSTRACT

The DOK1 gene is a putative tumour suppressor gene located on the human chromosome 2p13 which is frequently rearranged in leukaemia and other human tumours. We previously reported that the DOK1 gene can be mutated and its expression down-regulated in human malignancies. However, the mechanism underlying DOK1 silencing remains largely unknown. We show here that unscheduled silencing of DOK1 expression through aberrant hypermethylation is a frequent event in a variety of human malignancies. DOK1 was found to be silenced in nine head and neck cancer (HNC) cell lines studied and DOK1 CpG hypermethylation correlated with loss of gene expression in these cells. DOK1 expression could be restored via demethylating treatment using 5-aza-2'deoxycytidine. In addition, transduction of cancer cell lines with DOK1 impaired their proliferation, consistent with the critical role of epigenetic silencing of DOK1 in the development and maintenance of malignant cells. We further observed that DOK1 hypermethylation occurs frequently in a variety of primary human neoplasm including solid tumours (93% in HNC, 81% in lung cancer) and haematopoietic malignancy (64% in Burkitt's lymphoma). Control blood samples and exfoliated mouth epithelial cells from healthy individuals showed a low level of DOK1 methylation, suggesting that DOK1 hypermethylation is a tumour specific event. Finally, an inverse correlation was observed between the level of DOK1 gene methylation and its expression in tumour and adjacent non tumour tissues. Thus, hypermethylation of DOK1 is a potentially critical event in human carcinogenesis, and may be a potential cancer biomarker and an attractive target for epigenetic-based therapy.


Subject(s)
DNA Methylation , DNA-Binding Proteins/genetics , Head and Neck Neoplasms/genetics , Phosphoproteins/genetics , Promoter Regions, Genetic , RNA-Binding Proteins/genetics , Adult , Aged , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p16/genetics , DNA-Binding Proteins/antagonists & inhibitors , Decitabine , Female , Genes, Tumor Suppressor , Head and Neck Neoplasms/pathology , Humans , Male , Middle Aged , Phosphoproteins/antagonists & inhibitors , RNA-Binding Proteins/antagonists & inhibitors , Risk Factors , Tumor Suppressor Proteins/genetics
17.
Tumori ; 97(3): 328-34, 2011.
Article in English | MEDLINE | ID: mdl-21789011

ABSTRACT

AIMS AND BACKGROUND: Salivary gland malignancies are rare. The aim of our study was to investigate radiotherapy-related toxicity and clinical outcome in patients treated at our division with postoperative radiotherapy (pRT) for parotid tumors. METHODS AND STUDY DESIGN: Forty-three consecutive patients (32 with primary parotid tumors, 9 with parotid metastases and 2 with recurrent benign diseases) were retrospectively analyzed. RESULTS: The median follow-up was 28 months. Twenty and 5 patients had a follow-up longer than 2 and 5 years, respectively. Thirty-seven patients were alive and most of them (78%) were free from disease. The local and distant control rates were higher in patients with primary parotid tumors (94% and 87.5%) than in patients with parotid metastases (87.5% and 75%). Grade 3 radiotherapy-related acute toxicity of skin and mucosa was recorded in 20.9% and 28% of patients, respectively. Two patients (4.7%) had grade 4 skin toxicity. Late toxicity data were available for 33 (77%) patients. None of the patients developed severe (grade 3 and 4) late toxicity of soft tissues, skin or temporomandibular joints. CONCLUSIONS: Postoperative radiotherapy is a feasible treatment that was found to be effective mainly in patients with primary parotid tumors. Toxicity was acceptable but could probably be further reduced using more advanced radiotherapy techniques. Longer follow-up is required to achieve definitive results.


Subject(s)
Parotid Neoplasms/radiotherapy , Parotid Neoplasms/surgery , Radiotherapy, Conformal , Adenocarcinoma/radiotherapy , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Carcinoma, Mucoepidermoid/radiotherapy , Carcinoma, Mucoepidermoid/surgery , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Carcinosarcoma/radiotherapy , Carcinosarcoma/surgery , Cystadenocarcinoma/radiotherapy , Cystadenocarcinoma/surgery , Disease-Free Survival , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Europe , Feasibility Studies , Female , Humans , Male , Middle Aged , Mouth Mucosa/radiation effects , Neoplasm Recurrence, Local/diagnosis , Neoplasm Staging , Parotid Neoplasms/mortality , Parotid Neoplasms/pathology , Radiotherapy, Conformal/adverse effects , Radiotherapy, Conformal/methods , Retrospective Studies , Time Factors , Treatment Outcome
18.
Oral Oncol ; 47(3): 174-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21257337

ABSTRACT

Compartmental tongue surgery (CTS) is a surgical technique that removes the compartments (anatomo-functional units) containing the primary tumor, eliminating the disease and potential muscular, vascular, glandular and lymphatic pathways of spread and recurrence. Compartment boundaries are defined as each hemi-tongue bounded by the lingual septum, the stylohyoid ligament and muscle, and the mylohyoid muscle. In this non-randomized retrospective study we evaluated the oncologic efficacy of CTS in patients with squamous cell carcinoma (SCCA) of the tongue treated from 1995 to 2008. We evaluated 193 patients with primary, previously untreated cT2-4a, cN0, cN+, M0 SCCA with no contraindication to anesthesia and able to give informed consent. Fifty patients treated between October 1995 and July 1999 received standard surgery (resection margin >1cm); 143 patients treated between July 1999 and January 2008 received CTS. Study endpoints were: 5-year local disease-free, locoregional disease-free and overall survival. After 5years, local disease control was achieved in 88.4% of CTS patients (16.8% improvement on standard surgery); locoregional disease control in 83.5% (24.4% improvement) and overall survival was 70.7% (27.3% improvement). The markedly improved outcomes in CTS patients, compared to those treated by standard surgery, suggest CTS as an important new approach in the surgical management of tongue cancer.


Subject(s)
Carcinoma, Squamous Cell/surgery , Oral Surgical Procedures/methods , Tongue Neoplasms/surgery , Tongue/surgery , Adult , Carcinoma, Squamous Cell/pathology , Disease-Free Survival , Female , Humans , Italy , Male , Middle Aged , Retrospective Studies , Tongue/pathology , Tongue Neoplasms/pathology , Treatment Outcome
19.
Eur Arch Otorhinolaryngol ; 267(11): 1735-42, 2010 Nov.
Article in English | MEDLINE | ID: mdl-20499077

ABSTRACT

Eighty patients affected by supraglottic cancer were treated by transoral carbon dioxide laser surgery between 1989 and 2006 in two Italian institutions. Patient staging was as follows: 2 pTis, 20 pT1, 38 pT2, and 20 pT3. Simultaneous or 1-month delayed neck dissection (ND) was performed on 27 (34%) patients, unilaterally in 10 and bilaterally in 17. The pN category was as follows: 9 pN0, 6 pN1, 8 pN2b, and 4 pN2c. A total of 16 (20%) patients received complementary radiotherapy (RT) and 5 (6%) were subjected to chemo-RT for persistent tumor after re-excision due to positive margins, multiple lymph nodes, and/or extracapsular spread after ND. The last follow-up was in December 2008. The 5-year overall, disease-specific and disease-free survivals, local control with laser alone, and organ preservation rates calculated by Kaplan-Meier analysis were 84.4, 97.4, 88.3, 96, and 97.2%, respectively. Univariate analysis showed a statistically significant impact on disease-free survival, local control with laser alone, and organ preservation of pT category (p = 0.009, p = 0.01, and p = 0.03, respectively), while pN category and tumor stage negatively influenced disease-free survival (p = 0.007 and p = 0.01, respectively). This series confirms the good overall oncologic outcomes obtained by transoral laser surgery for Tis, T1, T2, and selected T3 supraglottic cancer with minimal pre-epiglottic space involvement.


Subject(s)
Carcinoma, Squamous Cell/surgery , Laryngeal Neoplasms/surgery , Laser Therapy/methods , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Female , Humans , Laryngeal Neoplasms/pathology , Laser Therapy/instrumentation , Lasers, Gas , Lymphatic Metastasis , Male , Microsurgery/instrumentation , Middle Aged , Neoplasm Invasiveness , Neoplasm Staging , Prognosis , Survival Rate , Treatment Outcome
20.
Eur Radiol ; 20(6): 1450-5, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20016904

ABSTRACT

OBJECTIVE: To evaluate the feasibility and performance of ultrasound-guided transcutaneous tru-cut biopsy (USGTCB) in selected patients (with stenosis of airways or difficult intubation or contraindication to general anaesthesia) with untreated or previously treated suspicious laryngo-hypopharyngeal masses. METHODS: Biopsies were performed with a free-hand technique by a single radiologist. Thirty-six USGTCBs were scheduled in 34 patients (24 males, 10 females; age range 47-95 years). Two USGTCBs were not performed, as lesions were not detectable: therefore, 16 USGTCBs were performed for an untreated mass suspicious for malignancy and 18 were performed for a mass suspicious for recurrence after radiotherapy alone, or associated with endoscopic laser surgery or chemotherapy. RESULTS: USGTCB diagnosed 25 squamous cell carcinomas (73.5%) and nine benign lesions (26.5%); no false positives and two false negatives were reported, both in patients previously treated with radiotherapy. The sensitivity, specificity, positive and negative predictive value of the technique was 92.5%, 100%, 100% and 77.7% respectively, with no major complications. CONCLUSION: Although biopsy under microlaryngoscopy remains the "gold-standard" technique, USGTCB is feasible, carries the advantages of avoiding general anaesthesia, is suitable for outpatients and is cost-effective. If applied to selected patients, it could be considered for the histological diagnosis of both primary and recurrent laryngo-hypopharyngeal masses.


Subject(s)
Biopsy/methods , Laryngeal Neoplasms/diagnosis , Pharyngeal Neoplasms/diagnosis , Surgery, Computer-Assisted/methods , Ultrasonography, Interventional/methods , Aged , Female , Humans , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...